Merck's Q2 Earnings Soar, Strong Guidance and New Indications Bolster Investment Narrative

Merck recently released its Q2 2026 results, showing sales of $16.61 billion and updated revenue guidance to $66.3-$67.3 billion for the year.

The company also announced regulatory progress on new indications for KEYTRUDA in Canada and ENFLONSIA's proposed expanded RSV use in the US and EU.

These developments highlight Merck's reliance on oncology and vaccine innovations to support its earnings outlook, despite acquisition-related losses and a complex late-stage pipeline.

The combination of stronger guidance and new RSV and oncology indications could reshape Merck's investment narrative, which is built around these areas and risks including KEYTRUDA patent expiry and pricing pressures.